Anavex appoints Dr. Dimitri Goundis to lead Clinical D...(lieve we will benefit enormously from hi...)

Date:4/16/2008

lieve we will benefit enormously from his wealth of drug development experience," said Dr. Kontzalis, Chief Executive Officer for ANAVEX. "Dr. Goundis' successful track record in clinical trials and his proven achievements in accelerating drug development programs will provide critical support for our business objectives as we look to file Investigational New Drug applications for three lead drug candidates and commence Phase 1 clinical trials of our lead Alzheimer's compound over the next 12 months."

"I am pleased to join the ANAVEX team at such a critical juncture in the company's growth and to be leading the development of a group of novel drug compounds with disease-modifying potential," said Dr. Goundis. "ANAVEX's approach to treating diseases is unique and unmatched in the industry. Our drug candidates have the potential to be safer and more effective than medications currently on the market because they aim to modify and treat the underlying causes, as opposed to just the symptoms, of Alzheimer's, epilepsy and various types of cancer.

Prior to joining ANAVEX, Dr. Goundis spent six years in various management roles with his most recent as Managing Director at Speedel Experimenta, the late-stage research unit of public biopharmaceutical company Speedel AG. During his tenure, Dr. Goundis led the successful development of SPP100 from Phase I through Phase IIb clinical trials, at which time Novartis exercised its license-back option. Today, SPP100 is sold in the United States under the trade name Tekturna and in Europe under the name Rasilez to treat hypertension. In addition, Dr. Goundis spent several years with lead responsibility for the company's entire development portfolio, including compounds in Phases I, II and III.

Dr. Goundis' background also includes director-level positions with The Medicines Company, where he was responsible for leading and managing the CNS business unit, and Roche, where he managed projects across a variety of th
'/>"/>

SOURCE Anavex Life Sciences Corp. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
2. Anavex strengthens Board of Directors
3. Anavex advances drug candidate for treatment of Alzheimers disease
4. Phytomedics Inc. Appoints Dr. Laurie Smaldone Alsup, MD., as President and Chief Executive Officer
5. Metabolex Appoints Donald Hill as Chief Financial Officer
6. Biopure Appoints New Independent Auditor
7. Indivumed Appoints Annette Kassen as Vice President Clinical Research
8. ADVENTRX Appoints Vice President of Manufacturing
9. Egenix, Inc. Appoints Dr. Daniel Petrylak Chairman of Scientific Advisory Board
10. NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director
11. Observant LLC Appoints Two New Directors to the Senior Management Team